Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts

Executive Summary

Pfizer's suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any of Pfizer's biosimilar Inflectra is reimbursed, but J&J says Pfizer has failed to show the value of Inflectra.


Related Content

Remicade Patent Fight: Janssen Loses Big, But Pfizer Not Out Of Woods
Biosimilar Legal Landscape: Lessons From 2017
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Can Janssen Revive Its Key Remicade Patent? Federal Circuit Hears Pitch
Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path
Biosimilars Statistical Guidance Reflects Early Development Approach
Too Bold By Half: Allergan’s Latest Moves And Pharma’s Leadership Deficit
Exclusive Remicade Contracts Are Slowing Biosimilar Uptake
Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
Pfizer Will Support Inflectra Launch With Dedicated Sales Force


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts